{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:25:38Z","timestamp":1791685538067,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008714","name":"Motor Neurone Disease Research Institute of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The copper compound Cu\n                    <jats:sup>II<\/jats:sup>\n                    (atsm) has progressed to phase 2\/3 testing for treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Cu\n                    <jats:sup>II<\/jats:sup>\n                    (atsm) is neuroprotective in mutant SOD1 mouse models of ALS where its activity is ascribed in part to improving availability of essential copper. However, SOD1 mutations cause only ~\u20092% of ALS cases and therapeutic relevance of copper availability in sporadic ALS is unresolved. Herein we assessed spinal cord tissue from human cases of sporadic ALS for copper-related changes. We found that when compared to control cases the natural distribution of spinal cord copper was disrupted in sporadic ALS. A standout feature was decreased copper levels in the ventral grey matter, the primary anatomical site of neuronal loss in ALS. Altered expression of genes involved in copper handling indicated disrupted copper availability, and this was evident in decreased copper-dependent ferroxidase activity despite increased abundance of the ferroxidases ceruloplasmin and hephaestin. Mice expressing mutant SOD1 recapitulate salient features of ALS and the unsatiated requirement for copper in these mice is a biochemical target for Cu\n                    <jats:sup>II<\/jats:sup>\n                    (atsm). Our results from human spinal cord indicate a therapeutic mechanism of action for Cu\n                    <jats:sup>II<\/jats:sup>\n                    (atsm) involving copper availability may also be pertinent to sporadic cases of ALS.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-55832-w","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T12:02:54Z","timestamp":1710158574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Evidence for disrupted copper availability in human spinal cord supports CuII(atsm) as a treatment option for sporadic cases of ALS"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-3566","authenticated-orcid":false,"given":"James B. W.","family":"Hilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kysenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0798-5338","authenticated-orcid":false,"given":"Jeffrey R.","family":"Liddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley I.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaine R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7777-4747","authenticated-orcid":false,"given":"Peter J.","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"55832_CR1","doi-asserted-by":"publisher","first-page":"42292","DOI":"10.1038\/srep42292","volume":"7","author":"JB Hilton","year":"2017","unstructured":"Hilton, J. B. et al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 7, 42292 (2017).","journal-title":"Sci. Rep."},{"key":"55832_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/21678421.2013.824000","volume":"14","author":"EJ McAllum","year":"2013","unstructured":"McAllum, E. J. et al. Therapeutic effects of CuII(atsm) in the SOD1G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 586\u2013590 (2013).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"55832_CR3","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1523\/JNEUROSCI.4196-13.2014","volume":"34","author":"BR Roberts","year":"2014","unstructured":"Roberts, B. R. et al. Oral treatment with CuII(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 34, 8021\u20138031 (2014).","journal-title":"J. Neurosci."},{"key":"55832_CR4","doi-asserted-by":"publisher","first-page":"44035","DOI":"10.1074\/jbc.M111.274407","volume":"286","author":"CP Soon","year":"2011","unstructured":"Soon, C. P. et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286, 44035\u201344044 (2011).","journal-title":"J. Biol. Chem."},{"key":"55832_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.01.020","volume":"89","author":"JR Williams","year":"2016","unstructured":"Williams, J. R. et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD mice co-expressing the Copper\u2013Chaperone-for-SOD. Neurobiol. Dis. 89, 1\u20139 (2016).","journal-title":"Neurobiol. Dis."},{"key":"55832_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ibror.2017.03.001","volume":"2","author":"FG Vieira","year":"2017","unstructured":"Vieira, F. G. et al. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2, 47\u201353 (2017).","journal-title":"IBRO Rep."},{"key":"55832_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104495","volume":"130","author":"MTH Kuo","year":"2019","unstructured":"Kuo, M. T. H., Beckman, J. S. & Shaw, C. A. Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model. Neurobiol Dis. 130, 104495 (2019).","journal-title":"Neurobiol Dis."},{"key":"55832_CR8","doi-asserted-by":"publisher","first-page":"19392","DOI":"10.1038\/s41598-021-98317-w","volume":"11","author":"JS Lum","year":"2021","unstructured":"Lum, J. S. et al. CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1(G93A) mice with a C57BL\/6 background. Sci. Rep. 11, 19392 (2021).","journal-title":"Sci. Rep."},{"key":"55832_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen, D. R. et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59\u201362 (1993).","journal-title":"Nature"},{"key":"55832_CR10","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1016\/S0021-9258(19)44055-6","volume":"248","author":"HJ Forman","year":"1973","unstructured":"Forman, H. J. & Fridovich, I. On the stability of bovine superoxide dismutase. The effects of metals. J. Biol. Chem. 248, 2645\u20132649 (1973).","journal-title":"J. Biol. Chem."},{"key":"55832_CR11","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.4103\/1673-5374.241445","volume":"13","author":"JR Morrice","year":"2018","unstructured":"Morrice, J. R., Gregory-Evans, C. Y. & Shaw, C. A. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen. Res. 13, 2050\u20132054 (2018).","journal-title":"Neural Regen. Res."},{"key":"55832_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1039\/C6MT00099A","volume":"8","author":"JB Hilton","year":"2016","unstructured":"Hilton, J. B., White, A. R. & Crouch, P. J. Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics 8, 1002\u20131011 (2016).","journal-title":"Metallomics"},{"key":"55832_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.expneurol.2018.06.006","volume":"307","author":"JB Hilton","year":"2018","unstructured":"Hilton, J. B., Kysenius, K., White, A. R. & Crouch, P. J. The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1(G37R) mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1. Exp. Neurol. 307, 118\u2013128 (2018).","journal-title":"Exp. Neurol."},{"key":"55832_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1084\/jem.20112285","volume":"209","author":"LW Hung","year":"2012","unstructured":"Hung, L. W. et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson\u2019s disease. J. Exp. Med. 209, 837\u2013854 (2012).","journal-title":"J. Exp. Med."},{"key":"55832_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s13311-016-0504-9","volume":"14","author":"MT Huuskonen","year":"2017","unstructured":"Huuskonen, M. T. et al. The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics 14, 519\u2013532 (2017).","journal-title":"Neurotherapeutics"},{"key":"55832_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00216-018-1362-6","volume":"411","author":"K Kysenius","year":"2019","unstructured":"Kysenius, K. et al. A versatile quantitative microdroplet elemental imaging method optimised for integration in biochemical workflows for low-volume samples. Anal. Bioanal. Chem. 411, 603\u2013616 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"55832_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1039\/c2an15792f","volume":"137","author":"D Hare","year":"2012","unstructured":"Hare, D., Austin, C. & Doble, P. Quantification strategies for elemental imaging of biological samples using laser ablation-inductively coupled plasma-mass spectrometry. Analyst 137, 1527\u20131537 (2012).","journal-title":"Analyst"},{"key":"55832_CR18","doi-asserted-by":"publisher","DOI":"10.3791\/55042","author":"DJ Hare","year":"2017","unstructured":"Hare, D. J. et al. Imaging metals in brain tissue by laser ablation\u2013inductively coupled plasma\u2013mass spectrometry (LA-ICP-MS). J. Vis. Exp. https:\/\/doi.org\/10.3791\/55042 (2017).","journal-title":"J. Vis. Exp."},{"key":"55832_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuroimage.2016.05.057","volume":"137","author":"DJ Hare","year":"2016","unstructured":"Hare, D. J. et al. Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer\u2019s disease frontal cortex. Neuroimage 137, 124\u2013131 (2016).","journal-title":"Neuroimage"},{"key":"55832_CR20","doi-asserted-by":"publisher","first-page":"27144","DOI":"10.1074\/jbc.M301988200","volume":"278","author":"SY Jeong","year":"2003","unstructured":"Jeong, S. Y. & David, S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278, 27144\u201327148 (2003).","journal-title":"J. Biol. Chem."},{"key":"55832_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00702-019-02138-1","volume":"127","author":"D Devos","year":"2020","unstructured":"Devos, D. et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis. J. Neural Transm. (Vienna) 127, 189\u2013203 (2020).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"55832_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nature09018","volume":"465","author":"L Banci","year":"2010","unstructured":"Banci, L. et al. Affinity gradients drive copper to cellular destinations. Nature 465, 645\u2013648 (2010).","journal-title":"Nature"},{"key":"55832_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/abio.1994.1408","volume":"221","author":"CW Levenson","year":"1994","unstructured":"Levenson, C. W. & Janghorbani, M. Long-term measurement of organ copper turnover in rats by continuous feeding of a stable isotope. Anal. Biochem. 221, 243\u2013249 (1994).","journal-title":"Anal. Biochem."},{"key":"55832_CR24","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1039\/b705989b","volume":"43","author":"AL Vavere","year":"2007","unstructured":"Vavere, A. L. & Lewis, J. S. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 43, 4893\u20134902 (2007).","journal-title":"Dalton Trans."},{"key":"55832_CR25","first-page":"1155","volume":"38","author":"Y Fujibayashi","year":"1997","unstructured":"Fujibayashi, Y. et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 38, 1155\u20131160 (1997).","journal-title":"J. Nucl. Med."},{"key":"55832_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.mito.2009.01.011","volume":"9","author":"M Ikawa","year":"2009","unstructured":"Ikawa, M. et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 9, 144\u2013148 (2009).","journal-title":"Mitochondrion"},{"key":"55832_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.nucmedbio.2011.02.016","volume":"38","author":"M Ikawa","year":"2011","unstructured":"Ikawa, M. et al. Evaluation of striatal oxidative stress in patients with Parkinson\u2019s disease using [62Cu]ATSM PET. Nuclear Med. Biol. 38, 945\u2013951 (2011).","journal-title":"Nuclear Med. Biol."},{"key":"55832_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1212\/WNL.0000000000001588","volume":"84","author":"M Ikawa","year":"2015","unstructured":"Ikawa, M. et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology 84, 2033\u20132039 (2015).","journal-title":"Neurology"},{"key":"55832_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1073\/pnas.1116227108","volume":"109","author":"PS Donnelly","year":"2012","unstructured":"Donnelly, P. S. et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copperII. Proc. Natl. Acad. Sci. U. S. A. 109, 47\u201352 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"55832_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nucmedbio.2011.08.008","volume":"39","author":"Y Yoshii","year":"2012","unstructured":"Yoshii, Y. et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less rho(0) cells and cybrids carrying MELAS mitochondrial DNA mutation. Nuclear Med. Biol. 39, 177\u2013185 (2012).","journal-title":"Nuclear Med. Biol."},{"key":"55832_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/635831","volume":"2013","author":"A Anand","year":"2013","unstructured":"Anand, A., Thakur, K. & Gupta, P. K. ALS and oxidative stress: The neurovascular scenario. Oxid. Med. Cell Longev. 2013, 635831 (2013).","journal-title":"Oxid. Med. Cell Longev."},{"key":"55832_CR32","first-page":"193","volume":"53","author":"JP Holland","year":"2009","unstructured":"Holland, J. P., Lewis, J. S. & Dehdashti, F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q. J. Nucl. Med. Mol. Imaging 53, 193\u2013200 (2009).","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"55832_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3389\/fnins.2018.00668","volume":"12","author":"XY Choo","year":"2018","unstructured":"Choo, X. Y. et al. CuII(atsm) attenuates neuroinflammation. Front. Neurosci. 12, 668 (2018).","journal-title":"Front. Neurosci."},{"key":"55832_CR34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bph.14881","volume":"177","author":"A Southon","year":"2020","unstructured":"Southon, A. et al. CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br. J. Pharmacol. 177, 656\u2013667 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"55832_CR35","unstructured":"NCT03204929. ClinicalTrials.org study # NCT03204929 \u201cDose escalation study of Cu(II)ATSM in Parkinson's disease\u201d."},{"key":"55832_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose, A. & Beal, M. F. Mitochondrial dysfunction in Parkinson\u2019s disease. J. Neurochem. 139, 216\u2013231 (2016).","journal-title":"J. Neurochem."},{"key":"55832_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ana.23817","volume":"73","author":"S Ayton","year":"2013","unstructured":"Ayton, S. et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 73, 554\u2013559 (2013).","journal-title":"Ann. Neurol."},{"key":"55832_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.neurobiolaging.2013.09.034","volume":"35","author":"KM Davies","year":"2014","unstructured":"Davies, K. M. et al. Copper pathology in vulnerable brain regions in Parkinson\u2019s disease. Neurobiol. Aging 35, 858\u2013866 (2014).","journal-title":"Neurobiol. Aging"},{"key":"55832_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-017-1726-6","volume":"134","author":"BG Trist","year":"2017","unstructured":"Trist, B. G. et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson\u2019s disease brain. Acta Neuropathol. 134, 113\u2013127 (2017).","journal-title":"Acta Neuropathol."},{"key":"55832_CR40","unstructured":"NCT02870634. ClinicalTrials.org study # NCT02870634 \u201cPhase 1 dose escalation and PK study of Cu(II)ATSM in ALS\/MND\u201d."},{"key":"55832_CR41","unstructured":"Rowe, D. B. et al. in 29th International Symposium on ALS\/MND (Glasgow, Scotland, 2018)."},{"key":"55832_CR42","unstructured":"NCT04082832. ClinicalTrials.org study # NCT04082832 \u201cCuATSM compared with placebo for treatment of ALS\/MND\u201d."},{"key":"55832_CR43","doi-asserted-by":"publisher","first-page":"e12919","DOI":"10.1111\/nan.12919","volume":"49","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. Neuropathol. Appl. Neurobiol. 49, e12919 (2023).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"55832_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12938","author":"JR Liddell","year":"2023","unstructured":"Liddell, J. R., Hilton, J. B. W. & Crouch, P. J. CuII(atsm) significantly decreases microglial reactivity in patients with sporadic amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. https:\/\/doi.org\/10.1111\/nan.12938 (2023).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"55832_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039216","volume":"7","author":"J Brettschneider","year":"2012","unstructured":"Brettschneider, J. et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PloS ONE 7, e39216 (2012).","journal-title":"PloS ONE"},{"key":"55832_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1039\/c3ay26248k","volume":"5","author":"DJ Hare","year":"2013","unstructured":"Hare, D. J., Lear, J., Bishop, D. P., Beavis, A. B. & Doble, P. A. Protocol for production of matrix-matched brain tissue standards for imaging by laser ablation-inductively coupled plasma-mass spectrometry. Analyt. Methods 5, 1915\u20131921 (2013).","journal-title":"Analyt. Methods"},{"key":"55832_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.freeradbiomed.2014.01.041","volume":"69","author":"S Ayton","year":"2014","unstructured":"Ayton, S. et al. Ceruloplasmin and beta-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radic. Biol. Med. 69, 331\u2013337 (2014).","journal-title":"Free Radic. Biol. Med."},{"key":"55832_CR48","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1016\/j.bbagen.2014.08.006","volume":"1840","author":"BX Wong","year":"2014","unstructured":"Wong, B. X. et al. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions. Biochim. Biophys. Acta 1840, 3299\u20133310 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"55832_CR49","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1021\/jf204970r","volume":"60","author":"X Li","year":"2012","unstructured":"Li, X. Improved pyrogallol autoxidation method: A reliable and cheap superoxide-scavenging assay suitable for all antioxidants. J. Agric. Food Chem. 60, 6418\u20136424 (2012).","journal-title":"J. Agric. Food Chem."},{"key":"55832_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1471-2105-7-123","volume":"7","author":"HJ Motulsky","year":"2006","unstructured":"Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear regression: A new method based on robust nonlinear regression and the false discovery rate. BMC Bioinform. 7, 123 (2006).","journal-title":"BMC Bioinform."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55832-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T16:02:31Z","timestamp":1710432151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55832-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55832-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.17.047704","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"1 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Collaborative Medicinal Development LLC has licensed intellectual property related to this subject from the University of Melbourne where the inventors include ARW and PSD.  AIB is a shareholder in Alterity Ltd, Cogstate Ltd, Brighton Biotech LLC, Grunbiotics Pty Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd.  He is a paid consultant for Collaborative Medicinal Development LLC and has a profit share interest in Collaborative Medicinal Development Pty Ltd.  PJC and JSB are unpaid consultants for Collaborative Medicinal Development LLC.  All other authors have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5929"}}